User:Mr. Ibrahem/Olaratumab

Olaratumab, sold under the brand name Lartruvo, was a medication used to treat soft tissue sarcoma. It is no longer recommended due to lack of benefit. It was given by injection into a vein.

Common side effects included nausea, tiredness, low white blood cells, pain, low platelets, abdominal pain, low potassium, headache, swelling, and allergic reactions. It is a monoclonal antibody which inhibits platelet-derived growth factor receptor alpha.

Olaratumab was approved for medical use in the United States and Europe in 2016. In 2019 it was withdrawn from market due to lack of benefit. It was sold for about 2,600 USD for 500 mg in the United States.